Study #2022-0231
Phase 1b of lurbinectedin in combination with weekly paclitaxel and bevacizumab in platinum-resistant ovarian cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Paclitaxel, Bevacizumab, Lurbinectedin
Description
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer
Study phase:
Phase I
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.